We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

SAN DIEGO, CA / TOKYO, Japan / MALVERN, PA — Fujirebio Holdings Inc., its subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. have announced the successful completion of a prospective sample ...

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of its biopharma business. Building on its successful collaborations in ...

Imagene AI, a pioneer in multimodal AI for precision oncology, announced a collaboration with Daiichi Sankyo to advance biomarker discovery and response prediction in oncology drug development.

TNO and Orikami are accelerating the deployment of digital biomarkers by combining scientific validation with a scalable, ...

WASHINGTON--(BUSINESS WIRE)--Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool ...

Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Add Yahoo as a preferred source to see more of our stories on Google. Guardant and Zephyr anticipate that its combination of multimodal data and AI/ML will drive precision medicine in oncology forward ...